Status:
ACTIVE_NOT_RECRUITING
Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).
Lead Sponsor:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions:
Myeloproliferative Neoplasm
Eligibility:
All Genders
18+ years
Brief Summary
This study will ultimately aim at developing a GIMEMA platform for collecting HRQoL and symptom burden information on Italian patients with Philadelphia chromosome negative MPN. The main objective of ...
Eligibility Criteria
Inclusion
- Patients diagnosed with Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (pre-PMF, overt-PMF) and post-ET/post-PV Myelofibrosis (MF), (i.e. Philadelphia chromosome negative myeloproliferative neoplasm (MPN)) according to 2016 WHO classification.
- Known IPSS/IPSET/DIPSS risk score category at time of initial diagnosis of PV, ET and PMF, respectively.
- Initial diagnosis of MPN within one year before date of registration.
- Having a full baseline PRO Evaluation completed.
- Adult patients (≥ 18 years old).
- Written informed consent provided.
Exclusion
- Having any kind of psychiatric disorder or major cognitive dysfunction problems hampering a self-reported evaluation.
- Not able to read and understand local language (i.e. Italian).
Key Trial Info
Start Date :
May 29 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 15 2025
Estimated Enrollment :
572 Patients enrolled
Trial Details
Trial ID
NCT04378855
Start Date
May 29 2020
End Date
November 15 2025
Last Update
September 23 2025
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Aon Ss. Antonio E Biagio E C. Arrigo - Alessandria - Soc Ematologia
Alessandria, Italy
2
Asl Di Asti, Ospedali Riuniti - Presidio Ospedaliero Cardinal G. Massaia - Sc Oncologia
Asti, Italy
3
Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto
Bari, Italy
4
Irccs Oncologico Istituto Tumori Giovanni Paolo Ii - Bari - Uo Ematologia
Bari, Italy